

Expanding the use of primaquine for the radical cure of *Plasmodium vivax*

Ric N Price^{1,2} and Nicholas M Douglas²

¹ Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK

² Global Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, NT, Australia

Corresponding author:

Ric N. Price

Global Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, NT, Australia

rprice@menzies.edu.au

© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

There is currently strong impetus for global malaria eradication with many National Malaria Control Programs setting ambitious elimination targets. Whilst intensified malaria control efforts have reduced the burden of falciparum malaria significantly, the fragile gains made thus far remain vulnerable to the threat of emergence and spread of multidrug resistant parasites. Outside of Sub-Saharan Africa, the decline in falciparum malaria has also been shadowed by a rise in the proportion of malaria due to *P. vivax*, which is now the predominant cause of malaria in these regions [1]. Vivax malaria is more difficult to eradicate than *P. falciparum* because it can form dormant liver stages (hypnozoites) that reactivate periodically, causing recurrent infections (relapses) and further transmission[2].

The primary objective of antimalarial treatment is to kill the pathogenic asexual parasite stages as rapidly as possible and thereby prevent or alleviate clinical symptoms and organ dysfunction. Schizontocidal agents have little efficacy against the mature sexual stages (gametocytes) of *P. falciparum* or the hypnozoites of *P. vivax* or *P. ovale*. Gametocytes and hypnozoites do not cause clinical disease directly, but they are critical for ensuring ongoing transmission of the parasite. Furthermore, reactivation of *P. vivax* hypnozoites results in recurrent episodes of malaria that can have a profound negative impact on health, particularly in women and infants from poorly resourced communities [3, 4].

If malaria elimination targets are to be achieved, there will need to be more aggressive use of 'radically curative' drug regimens that are capable of eliminating all parasite stages from the body, including gametocytes and hypnozoites. Both patients with clinical disease and the large numbers of apparently healthy individuals who harbour transmissible malaria parasites need to be targeted [5]. The only widely available drug to treat the mature gametocytes of *P. falciparum* and the hypnozoites of *P. vivax* is primaquine (PQ), a drug which can cause severe haemolytic anaemia when administered to patients with glucose-6-phosphate-dehydrogenase (G6PD) enzyme deficiency. G6PD deficiency is the most common enzymopathy worldwide, affecting an estimated 400 million people. Recent WHO guidelines advocate that, where possible, all patients should be tested for G6PD deficiency prior to administration of primaquine, however few malaria endemic countries have yet to incorporate this into national guidelines [6, 7]. Whilst primaquine has been shown to be well tolerated in G6PD normal children over the age of 12 months, there are almost no safety data for its use in young infants. Moreover, it is not possible to diagnose G6PD deficiency *in utero* or before the age of about 6 months using standard G6PD assays available in resource poor countries. For these reasons, prescription of primaquine is currently contraindicated during pregnancy and for at least the first 6 months that mothers are lactating [6]. Since women in many malaria endemic settings are

either pregnant or breast feeding for most of their reproductive years, they may be denied radical cure for many years, and potentially decades. The ongoing carriage of hypnozoites puts subsequent pregnancies at risk from relapsing vivax malaria, contributing to preterm delivery, maternal anaemia, and perinatal mortality [4].

In this issue of *Clinical Infectious Diseases*, Gilder and colleagues report the results of the first pharmacokinetic study to determine whether primaquine is excreted into breast milk and therefore whether primaquine should be contraindicated during lactation (REF). The authors enrolled 20 G6PD-normal mothers from northern Thailand, who required primaquine for radical cure of *P. vivax* infection and who were breast feeding infants more than 28 days old. Serial venous blood and breast milk samples were taken from the mothers during a 14 day high-dose primaquine regimen (7mg/kg total dose) along with capillary blood samples from their breast fed infants. The estimated dose of primaquine received by the infants from breast milk was less than 3 µg/kg/day, equivalent to ~0.5% of that which would be administered directly during a standard weight-based primaquine regimen. Only one of the infant blood samples had a primaquine level above the limit of detection and the concentration measured was negligible. Whilst there are few data on the safety of primaquine in infants, there is no evidence that primaquine is more toxic to infants than adults. Since a single dose of 0.25mg/kg has been shown to cause no significant haemolysis even in G6PD deficient individuals, it is highly likely that a total dose more than 6 fold lower would be safe, even in deficient individuals. These results are extremely reassuring. Further data are needed to confirm tolerability in infants less than 28 days, but in the meantime, treatment policy should be changed so that G6PD-normal mothers with a history of *P. vivax* malaria can be treated with a radically curative course of primaquine provided they are at least 4 weeks post-partum. Such a strategy will reduce the risks to mother and baby of malaria in future pregnancies and reduce parasite transmission. Expanding the eligibility of radical cure to include lactating mothers has potential to reduce the global burden of malaria.

The authors should be applauded for addressing a neglected area that has, over the last 60 years, effectively denied millions of lactating women appropriate antimalarial treatment. The study also highlights the importance of defining antimicrobial policy through detailed pharmacokinetic studies in vulnerable populations. Collecting relevant samples from pregnant women and young children is particularly challenging, and thus recommended dosing regimens are frequently extrapolated from studies in older children and non-pregnant adults, assuming that the pharmacokinetic profiles are similar; often this assumption is patently invalid. Malaria treatment guidelines derived by such means have resulted in under-dosing of sulphadoxine-pyrimethamine in children, [8] of artemether-

lumefantrine in pregnant women [9], and of dihydroartemisinin-piperaquine in low weight children [10]. Technological advances have enabled quantification of antimicrobial agents and their metabolites reliably from increasingly smaller sample volumes, allowing carefully designed and conducted studies, like the one by Gilder and colleagues, to define optimal treatment strategies in those who need them most.

Funding: RNP is a Wellcome Trust Senior Research Fellow.

Conflict of Interest: We declare that we have no conflicts of interest.

References:

1. World Health O. World Malaria Report: 2017. Geneva:WHO **2017**.
2. White NJ. Determinants of relapse periodicity in *Plasmodium vivax* malaria. *Malar J* **2011**; 10: 297.
3. Douglas NM, Lampah DA, Kenangalem E, et al. Major burden of severe anemia from non-falciparum malaria species in southern papua: a hospital-based surveillance study. *PLoS Med* **2013**; 10(12): e1001575.
4. McGready R, Lee SJ, Wiladphaingern J, et al. Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. *Lancet Infect Dis* **2012**; 12(5): 388-96.
5. Tanner M, Greenwood B, Whitty CJ, et al. Malaria eradication and elimination: views on how to translate a vision into reality. *BMC Med* **2015**; 13: 167.
6. World Health Organisation. Guidelines for the treatment of malaria – 3rd edition. Geneva: WHO, **2015**.
7. Thriemer K, Ley B, Bobogare A, et al. Challenges for achieving safe and effective radical cure of *Plasmodium vivax*: a round table discussion of the APMEN Vivax Working Group. *Malar J* **2017**; 16(1): 141.
8. Barnes KI, Little F, Smith PJ, Evans A, Watkins WM, White NJ. Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. *Clin Pharmacol Ther* **2006**; 80(6): 582-96.
9. McGready R, Tan SO, Ashley EA, et al. A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated plasmodium falciparum treatment in pregnancy. *PLoS Med* **2008**; 5(12): e253.
10. Hoglund RM, Workman L, Edstein MD, et al. Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis. *PLoS Med* **2017**; 14(1): e1002212.